Prodrugs of natural anthracycleves suited for antibody directed enzyme prodrug therapy (ADEPT) and prodrug monotherapy (PMT)

Studies in Natural Products Chemistry

Volumn 21, Issue PART B, 2000, Pages 157-180

  Michel, S ^a   Desbene, S ^a   Gesson, J P ^b   Monneret, C ^a   Tillequin, F ^a  

^a CNRS   (France)

^b UNIVERSITÉ DE POITIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0003191284     PISSN: 15725995     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1572-5995(00)80006-X     Document Type: Article

References (76)

1. Arcamone F. Anticancer Agents Based on Natural Prodructs Models. In: Cassady J.M., and Douros J.D. (Eds) (1980), Academic Press, New-York 1-41
2. In: Lawn J.W. (Ed). Anthracycline and Anthracenedione-based Anticancer Agents (1988), Elsevier, Amsterdam
3. In: Priebe W. (Ed). New Analogues, Methods of Delivery, and Mechanisms of Action. ACS Symposium Series 574 (1995), American Chemical Society, Washington Anthracycline Antibiotics
4. Arcamone F., Animati F., Capranico G., Lombardi P., Pratesi G., Manzini S., Supino R., and Zunino F. Pharmacol. Ther. 76 (1997) 117
5. Weiss R.B. Seminars in oncology 19 (1992) 670
6. Hortobagyi G.N. Drugs 54 Suppl. 4 (1997) 1
7. Gilladoga A.G., Manuel C., Tan C.T.C., Wollner N., Sternberg S.S., and Murphy M.L. Cancer 37 (1976) 1070
8. Bristow M.R., Thomson P.D., Martin R.P., Mason J.W., Billingham M.E., and Harrison D.C. Am. J. Med. 65 (1978) 823
9. Bristow M.R., Mason J.W., Billingham M.E., and Daniels J.R. Am. Heart J. 102 (1981) 709
10. Sulkes A., and Collins J.M. Cancer Treat. Rep. 71 (1987) 229
11. Basser R.L., and Green M.D. Cancer Treat. Rev. 19 (1993) 57
12. Nowak D., and Drzewaki M.D. Cancer J. 9 (1996) 296
13. Gille L., and Nohl H. Free Radic. Biol. Med. 23 (1997) 775
14. Singal P.K., Iliskovic N., Li T., and Kumar D. ASEB J. 11 (1997) 931
15. In: Gupta S., and Tsuro T. (Eds). Multidrug Resistance in Cancer Cells - Molecular, Biochemical, Physiological and Biological Aspects (1996), John Wiley, Chichester
16. Kolaczkowski M., and Goffeau A. Pharmacol. Ther. 76 (1997) 219
17. Ling V. Cancer 69 (1992) 2603
18. Ling V. Cancer Chemother. Pharmacol. 40 (1997) 53
19. Kavallaris M. Anticancer Drugs 8 (1997) 17
20. Berger W., Elbling L., Hauptmann E., and Micksche M. Int. J. Cancer 73 (1997) 84
21. Connors T.A. (1978) 979
22. Bagshawe K.D. Br. J. Cancer 56 (1987) 531
23. Bagshawe K.D., Springer C.J., Searle F., Antoniw P., Sharma S.K., Melton R.G., and Sherwood R.F. Br. J. Cancer 58 (1988) 700
24. Bagshawe K.D. Br. J. Cancer 60 (1989) 275
25. Senter P.D., Saulnier M.G., Schreiber G.J., Hirschberg D.L., Brown J.P., Hellstrom I., and Hellstrom K.E. Proc. Natl. Acad. Sci. USA 85 (1988) 4842
26. Senter P.D., Schreiber G.J., Hirschberg D.L., Ashe S.A., Hellstrom K.E., and Hellstrom I. Cancer. Res. 49 (1989) 5789
27. Bagshawe K.D. Clin. Pharmacokinet. 27 (1994) 368
28. Bagshawe K.D. J. Controlled Rel. 28 (1994) 187
29. Huennekens F.M. Tibtech 12 (1994) 234
30. Wallace P.M., and Senter P.D. Meth. Find. Exp. Clin. Pharmacol. 16 (1994) 505
31. Jungheim L.N., and Shepherd T.A. Chem. Rev. 94 (1994) 1553
32. Deonarain M.P., and Epenetos A.A. Br. J. Cancer 70 (1994) 786
33. Bagshawe K.D. Drug Development Res. 34 (1995) 220
34. Melton R.G., and Sherwood R.F. J. Natl. Cancer Inst. 88 (1996) 153
35. Sinhababu A.K., and Thakker D.R. Adv. Drug Deliv. Rev. 19 (1996) 241
36. Hay M.P., and Denny W.A. Drugs Fut. 21 (1996) 917
37. Niculescu-Duvaz I., and Springer C.J. Adv. Drug Deliv. Rev. 26 (1997) 151
38. Bagshawe K.D., Sharma S.K., Springer C.J., Antoniw P., Rogers G.T., Burke P.J., Melton R., and Sherwood R.F. Antibody lmmunoconjugates Radiopharmaceuticals 4 (1991) 915
39. Bagshawe K.D., Sharma S.K., Springer C.J., and Antoniw P. Tumor Targeting 1 (1995) 17
40. Bagshawe K.D., and Begent R.H.J. Adv.Drug Deliv. Rev. 22 (1996) 365
41. Sharma S.K. Adv.Drug Deliv. Rev. 22 (1996) 369
42. Senter P.D. FASEB J. 4 (1990) 188
43. Sahin U., Hartmann F., Senter P.D., Pohl C., Engert A., Diehl V., and Pfreundschuh M. Cancer Res. 50 (1990) 6944
44. Wallace P.M., and Senter P.D. Bioconj. Chem. 2 (1991) 349
45. Bosslet K., Steinsträsser A., Schwartz A., Hartus H.P., Lüben G., Kuhlman L., and Sedlacek H.H. Eur. J. Nucl. Med. 14 (1988) 523
46. Jones P.T., Dear P.H., Foote J., Neuberger M.S., and Winter G. Nature 321 (1986) 522
47. Reichmann L., Clark M., Waldmann H., and Winter G. Nature 332 (1988) 323
48. Bosslet K., Czech J., Lorenz P., Sedlacek H.H., Schuermann M., and Seemann G. Br. J. Cancer 65 (1992) 234
49. Haisma H.J., Brakenhoff R.H., Meulen-Muileman I.v.d., Pinedo H.M., and Boven E. Cancer Immunol. Immunother. 45 (1998) 266
50. Eur. Patent EP 0441 218 A2. Gerken M., Bosslet K., Seemann G., Hoffmann D., and Sedlacek H.H. Anthracyclin-glycosyl-prodrugs, Verfahren zu ihrer Herstellung und ihre Verwendung in Kombination mit funktionalisierten tumorspezifischen Enzymconjugaten (1991)
51. Wakselman M., and Guibé-Jampel E. J. Chem. Soc. Chem. Comm. (1973) 593
52. Wakselman M., and Nouv. J.Chim. (1983) 439
53. Carl P.L., Chakravarty P.K., and Katzenellenbogen J.A. J. Med Chem. 24 (1981) 479
54. Eur. Patent EP 0511 917 A1. Jacquesy J.-C., Gesson J.-P., Monneret C., Mondon M., Renoux B., Florent J.-C., Koch M., Tillequin F., Sedlacek H.H., Kolar C., and Gaudel G. Prodrogues glycosylées, leurs procédes de préparation et leurs utilisations (1991)
55. Andrianomenjanahary, S., Dong X., Florent J.-C., Gaudel G., Gesson J.-P., Jacquesy J.-C., Koch M., Michel S., Mondon M., Monneret C., Petit P., Renoux B., and Tillequin F. Bioorg. Med. Chem. Lett. 2 (1992) 1093
56. Helferich B., and Schmitz-Hillebrecht E. Ber. Dtsch. Chem. Ges. 66 (1933) 378
57. Conchie J., and Levy G.A. Meth. Carbohydr. Chem. 2 (1963) 345
58. Helferich B., and Jung K.-H. Ann. Chem. 589 (1954) 11
59. Gingras M., and Chan T.H. Tetrahedron Lett. 30 (1989) 279
60. Thomson A., and Wolfrom M.L. Meth. Carbohydr. Chem. 2 (1963) 215
61. Gesson J.-P., Jacquesy J.-C., Mondon M., Petit P., Renoux B., Andrianomenjanahary S., Dufat-Trinh Van H., Koch M., Michel S., Tillequin F., Florent J.-C., Monneret C., Bosslet K., Czech J., and Hoffmann D. Anti-cancer Drug Design. 9 (1994) 409
62. Koch M., and Monneret C. Recent Res. Devel. Chem. Pharm. Sci. 1 (1996) 35
63. Azoulay M., Florent J.-C., Monneret C., Gesson J.-P., Jacquesy J.-C., Tillequin F., Koch M., Bosslet K., Czech J., and Hoffmann D. Anti-cancer Drug Design 10 (1995) 441
64. Excoffier G., Gagnaire D., and Utille J.-P. Carbohydr. Res. 39 (1975) 368
65. Bosslet, K., Personnal Communication.
66. Florent J.-C., Dong X., Gaudel G., Mitaku S., Monneret C., Gesson J.-P., Jacquesy J.-C., Mondon M., Renoux B., Andrianomenjanahary S., Michel S., Koch M., Tillequin F., Gerken M., Czech J., Straub R., and Bosslet K.J. Med. Chem. 41 (1998) 3572
67. Bollenback G.N., Long J.W., Benjamin D.G., and Lindquist J.A. J. Am. Chem. Soc. 77 (1955) 3310
68. Buehler C.A., Brown R.L., Holbert J.M., Fulmer J.G., and Parker G.W. J. Org. Chem. 6 (1941) 902
69. Bosslet K., Czech J., and Hoffmann D. Cancer Res. 54 (1994) 2151
70. Haisma H.J., van Muijen M., Pinedo H.M., and Boven E. Cell Biophysics. 24/25 (1994) 185
71. Haisma H.J., Boven E., Meulen-Muileman, van Muijen M., de Jong J., van Der Vigh W.J.F., and Pinedo H.M. Br. J. Cancer. 66 (1992) 474
72. Leenders R.G.G., Gerrits A.A., Ruijtenbeek R., Scheeren J.W., and Haisma H.J. Tetrahedron Lett. 36 (1995) 1701
73. Houba P.H.J., Leenders R.G.G., Boven E., Scheeren J.W., Pinedo H.M., and Haisma H.J. Biochem. Pharmacol. 52 (1996) 455
74. Bosslet K., Staub R., Blumrich M., Czech J., Gerken M., Sperker B., Kroemer H.-K., Gesson J.-P., Koch M., and Monneret C. Cancer Res. 58 (1998) 1195
75. Bosslet K., Czech J., and Hoffmann D. Tumor Targeting 1 (1995) 45
76. Mündter T.E., Sperker B., Kivistö K.T., McClellan M., Fritz P., Friedel G., Linder A., Bosslet K., Toomes H., Dierkesmann R., and Kroemer H.K. Cancer Res. 57 (1997) 2440